Reviewer 3 
R3C1. 
PARCIALMENTE RESOLVIDO - claudio

The abstract states: "2,087 studies explicitly reported the use of brain devices... resulting in a true positive 
rate of 55.79%." The term "true positive rate" is typically used in classification/diagnostic contexts 
(sensitivity = TP/(TP+FN)). In a literature search, this terminology is confusing. What constitutes a "false 
negative" in your search strategy? Are you referring to the precision of your search query (relevant papers / 
total retrieved papers)? Please clarify this metric. If you mean that 55.79% of the screened papers were 
relevant (i.e., actually used brain devices), use standard systematic review terminology such as "inclusion 
rate" or "relevance rate." Provide a PRISMA flow diagram showing the exact numbers at each screening 
stage. 
 
1. Substituir completamente o termo true positive rate por “inclusion rate” em todo o artigo. 
2. Inserir na seção Methods uma definição formal: 
●​
Inclusion rate = (nº de estudos que realmente usaram o dispositivo) / (nº total de registros 
recuperados). 
3. Deixar claro que: 
●​
não há “false negatives”; 
●​
trata-se de eficiência da estratégia de busca, não métrica diagnóstica. 
4. Garantir que o fluxograma PRISMA mostre: 
●​
registros recuperados; 
●​
excluídos por falso positivo (nome ambíguo, menção sem uso); 
●​
incluídos finais. 
→ Onde: Abstract, Methods, Results, PRISMA Figure 
 
Response To Reviewers 
We agree with the reviewer that the term true positive rate is inappropriate in the context of a 
literature search. The manuscript has been revised to replace this term with inclusion rate, which 
is consistent with systematic review terminology. The inclusion rate is now explicitly defined in the 
Methods section as the proportion of retrieved records that explicitly applied the named brain 
device as an experimental or clinical tool, reflecting the precision of the device-specific search 
queries, rather than sensitivity or recall. The Abstract and Results sections were updated 
accordingly to report that 2,087 of 3,741 unique records met the inclusion criteria, yielding an 
overall inclusion rate of 55.79%. A PRISMA flow diagram has also been added to report the 
number of records retrieved, duplicates removed, records screened, and studies included at each 
stage. 
 
 
​
R3C2. 
STATUS - claudio   
The manuscript states that 96 devices were "tracked in the market" but does not describe the market survey 
methodology. How were the 96 devices identified? Was there a systematic search of manufacturer websites, 
regulatory databases (e.g., FDA, CE marking), or commercial catalogs? Were devices from China, India, or 
other non-Western markets included? Requirement: Add a dedicated subsection in the Methods describing 
the device identification protocol. Include: 1. Search terms used (e.g., "wireless EEG," "portable fNIRS"); 2. 
Databases/sources consulted (e.g., Google Scholar, manufacturer websites, ResearchGate equipment lists); 
3. Inclusion/exclusion criteria (e.g., "commercially available as of August 2025," "wireless only"); 4. A 
supplementary table listing all 96 devices with manufacturer, model number, and year of market entry. 
 
1. Criar uma subseção nova em Methods chamada: “Device identification and market survey 
protocol” 
2. Descrever claramente:

●​
termos de busca usados (ex.: “wireless EEG”, “portable fNIRS”); 
●​
fontes consultadas: 
○​
sites de fabricantes; 
○​
Google Scholar; 
○​
catálogos comerciais; 
○​
literatura científica. 
3. Especificar critérios de inclusão: 
●​
dispositivo comercialmente disponível; 
●​
portátil e/ou wireless; 
●​
EEG e/ou fNIRS; 
●​
disponível até mês/ano definido. 
4. Especificar critérios de exclusão: 
●​
protótipos acadêmicos; 
●​
dispositivos descontinuados; 
●​
softwares sem hardware. 
5. Confirmar explicitamente: 
●​
inclusão de dispositivos de mercados não ocidentais (China, Índia). 
6. Criar uma tabela suplementar com: 
●​
fabricante; 
●​
modelo; 
●​
ano de entrada no mercado. 
→ Onde: Methods + Supplementary Material 
 
RESPONSE TO REVIEWERS 
Text… 
 
 
 
R3C3. 
STATUS - claudio   
The manuscript reports percentages (e.g., Epoc X = 19.30%, OpenBCI = 4.81%) but lacks deeper statistical 
analysis. These percentages suggest a highly skewed distribution (a few devices dominate, while most have 
minimal adoption). This is a classic "long-tail" phenomenon. Requirement: 1. Provide a Lorenz curve or Gini 
coefficient to quantify the inequality in research adoption; 2. Perform a correlation analysis: 2.1. Does 
device cost negatively correlate with adoption rate? 2.2. Does channel count positively correlate with 
citation frequency? 2.3. Use regression analysis to identify which technical specifications (e.g., open API, dry 
electrodes, price) predict research adoption. 
 
1. Gerar uma Curva de Lorenz para adoção dos dispositivos. 
2. Calcular o coeficiente de Gini da distribuição de citações. 
3. Fazer análises simples: 
●​
correlação entre preço vs adoção; 
●​
correlação entre nº de canais vs adoção. 
4. Rodar uma regressão exploratória com variáveis como: 
●​
open API (sim/não); 
●​
tipo de eletrodo (seco/molhado); 
●​
preço aproximado. 
5. Deixar explícito que a análise é exploratória, não causal. 
→ Onde: Results + Figures + Methods (estatística) 
 
RESPONSE TO REVIEWERS 
Text…

R3C4.  
PARCIALMENTE RESOLVIDO - claudio 
The abstract mentions "a significant gap between consumer-grade and research-grade technologies" but 
does not define these categories. Is the classification based on price, signal quality (SNR), regulatory 
approval (FDA Class II), or intended use? Requirement: 1. Provide explicit criteria for this classification. For 
example: 1.1. Consumer-grade: < $500, < 8 channels, dry electrodes, primarily marketed for 
meditation/gaming; 1.2. Research-grade: > $5,000, > 32 channels, wet/gel electrodes, medical-grade 
certification. 
 
1. Criar critérios explícitos em Methods ou Results: 
2. Aplicar essa classificação de forma consistente. 
3. Ajustar o Abstract para refletir essa definição. 
4. Inserir na tabela a classificação “Grade: consumer / research / clinical” 
→ Onde: Methods, Results, Abstract 
 
RESPONSE TO REVIEWERS 
We have added an explicit definitional paragraph clarifying that the classification of EEG devices is based on 
intended use, technical specifications, signal quality, and regulatory status. This paragraph was placed 
before the detailed technical comparison to improve conceptual clarity and directly address the reviewer’s 
concern. This classification framework is supported by prior studies distinguishing consumer-grade, 
research-grade, and clinical-grade EEG systems based on these criteria (Chuang and Lin, 2019; Doudou et 
al., 2020; Huang et al., 2020; Grasso-Cladera et al., 2023). 
 
 
​
R3C5. 
STATUS - Encarregado 
The manuscript mentions devices "currently available" but does not analyze temporal evolution. The 
neurotechnology market has evolved rapidly. Early devices (e.g., NeuroSky MindWave, 2009) differ 
significantly from recent models (e.g., Kernel Flow, 2023). Requirement: 1. Add a timeline figure showing 
when each device entered the market; 2. Analyze trends: 2.1. Has the average channel count increased over 
time? 2.2. Has the price per channel decreased (Moore's Law for neurotechnology)? 2.3. When did wireless 
architectures become dominant? 
 
1. Criar uma linha do tempo mostrando ano de entrada de cada dispositivo no mercado. 
2. Analisar tendências simples: 
●​
aumento do nº médio de canais ao longo do tempo; 
●​
redução do custo por canal; 
●​
transição para arquiteturas wireless. 
3. Relacionar essas tendências à evolução tecnológica geral. 
→ Onde: Results, Figures, Discussion 
 
RESPONSE TO REVIEWERS 
Text…

R3C6.  
STATUS - Encarregado 
The manuscript states "125 models and variants" but does not explain how variants were handled in the 
analysis. If a study used "Epoc" (2009) and another used "Epoc X" (2018), were these counted separately or 
aggregated? The Epoc X has significant hardware improvements (5-electrode reference system, improved 
wireless). Clarify the aggregation strategy. If variants were pooled, justify this decision. If kept separate, 
provide a breakdown showing which specific variant was most cited. 
 
1. Explicar claramente a estratégia adotada: 
●​
variantes agrupadas por família ou 
●​
variantes tratadas separadamente. 
2. Justificar a decisão: 
●​
semelhança técnica; 
●​
continuidade comercial. 
3. Se variantes foram separadas, apresentar qual versão foi mais citada. 
4. Incluir essa explicação em Methods. 
→ Onde: Methods, Supplementary Table 
 
RESPONSE TO REVIEWERS 
Text…